Table 2. Treatment of patients with KRAS mutation (N=66).
| Factors | Number (%) |
|---|---|
| 1st-line chemotherapy | |
| Taxanes-based | 8 (12.1) |
| Pemetrexed-based | 48 (72.7) |
| Gemcitabine-based | 3 (4.5) |
| No | 7 (10.6) |
| 1st-line angiogenesis inhibitors | |
| Yes | 28 (42.4) |
| No | 38 (57.6) |
| 1st-line immune therapy | |
| Yes | 10 (15.2) |
| No | 56 (84.8) |
| 2nd-line therapy | |
| Yes | 37 (56.1) |
| No | 27 (40.9) |
| Unknown | 2 (3.0) |
| 2nd-line therapy | |
| Taxanes-based | 20 (30.3) |
| Pemetrexed-based | 8 (12.1) |
| Gemcitabine-based | 3 (4.5) |
| Other | 6 (9.1) |
| No | 29 (43.9) |
| 2nd-line angiogenesis inhibitors | |
| Yes | 9 (13.6) |
| No | 28 (42.4) |
| 2nd-line immune therapy | |
| Yes | 9 (13.6) |
| No | 28 (42.4) |
| 3rd-line therapy | |
| Yes | 17 (25.8) |
| No | 49 (74.2) |
| 4th-line therapy | |
| Yes | 8 (12.1) |
| No | 58 (87.9) |
| 5th-line therapy | |
| Yes | 3 (4.5) |
| No | 63 (95.5) |
| Posterior line therapy | 28 (100.0) |
| Chemotherapy | 8 (28.6) |
| Angiogenesis inhibitors | 5 (17.9) |
| Chemotherapy + angiogenesis inhibitors | 5 (17.9) |
| Chemotherapy + immune therapy | 2 (7.1) |
| Angiogenesis inhibitors + immune therapy | 5 (17.9) |
| TKI | 2 (7.1) |
| Chemotherapy + TKI | 1 (3.6) |
Posterior line therapy: 3rd-line, 4th-line and 5th-line therapy. KRAS, Kirsten rat sarcoma viral oncogene homolog; TKI, tyrosine-kinase inhibitor.